Market Analysis and Insights: Global Cell Line Generation Market
The global Cell Line Generation market size is projected to reach US$ 3,184.5 million by 2028, from US$ 1,678.4 million in 2021, at a CAGR of 9.95% during 2022-2028.
Fully considering the economic change by this health crisis, Knockout Cell Lines accounting for 49.39% of the Cell Line Generation global market in 2021, is projected to value US$ 1,711.7 million by 2028, growing at a revised 22.55% CAGR in the post-COVID-19 period. While Pharmaceutical Industry segment is altered to an 10.19% CAGR throughout this forecast period.
China Cell Line Generation market size is valued at US$ 102.1 million in 2021, while the North America and Europe Cell Line Generation are US$ 560.7 million and US$ 619.1 million, severally. The proportion of the North America is 33.41% in 2021, while China and Europe are 6.08% and 36.89% respectively, and it is predicted that China proportion will reach 11.30% in 2028, trailing a CAGR of 21.48% through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR 12.32%, 8.46%, and 8.52% respectively for the next 6-year period. As for the Europe Cell Line Generation landscape, Germany is projected to reach US$ 234.7 million by 2028 trailing a CAGR of 7.89% over the forecast period.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cell Line Generation market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cell Line Generation market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cell Line Generation market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cell Line Generation market.
Global Cell Line Generation Scope and Market Size
Cell Line Generation market is segmented by players, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cell Line Generation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2017-2028.
By Company
Boehringer Ingelheim BioXcellence
Lonza
WuXi Biologics
Thermo Fisher Scientific
Sartorius
Merck
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Porton Biologics
Chempartner Pharmatech
Rentschler Biopharma
ProBioGen
AGC Biologics
OPM Biosciences
Charles River Laboratories
Mycenax Biotech
JOINN Laboratories
Segment by Type
Knockout Cell Lines
Overexpression Cell Lines
Inducible Expression Cell Lines
Knockdown Cell Lines
Knockin Cell Lines
Others
Segment by Application
Pharmaceutical Industry
Biological Industry
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
South America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
TABLE OF CONTENTS
TABLE OF CONTENTS
1 REPORT OVERVIEW 1
- 1.1 STUDY SCOPE 1
- 1.2 MARKET ANALYSIS BY TYPE 1
- 1.2.1 GLOBAL CELL LINE GENERATION MARKET SIZE GROWTH RATE BY TYPE: 2017 VS 2021 VS 2028 1
- 1.2.2 KNOCKOUT CELL LINES 2
- 1.2.3 OVEREXPRESSION CELL LINES 2
- 1.2.4 INDUCIBLE EXPRESSION CELL LINES 3
- 1.2.5 KNOCKDOWN CELL LINES 3
- 1.2.6 KNOCKIN CELL LINES 3
- 1.2.7 OTHERS 4
- 1.3 MARKET BY APPLICATION 4
- 1.3.1 GLOBAL CELL LINE GENERATION MARKET SHARE BY APPLICATION: 2017 VS 2021 VS 2028 4
- 1.3.2 PHARMACEUTICAL INDUSTRY 5
- 1.3.3 BIOLOGICAL INDUSTRY 5
- 1.4 STUDY OBJECTIVES 5
- 1.5 YEARS CONSIDERED 6
2 GLOBAL GROWTH TRENDS 7
- 2.1 GLOBAL CELL LINE GENERATION MARKET PERSPECTIVE (2017-2028) 7
- 2.2 CELL LINE GENERATION GROWTH TRENDS BY REGION 8
- 2.2.1 CELL LINE GENERATION MARKET SIZE BY REGION: 2017 VS 2021 VS 2028 8
- 2.2.2 CELL LINE GENERATION HISTORIC MARKET SIZE BY REGION (2017-2022) 9
- 2.2.3 CELL LINE GENERATION FORECASTED MARKET SIZE BY REGION (2023-2028) 10
- 2.3 CELL LINE GENERATION MARKET DYNAMICS 10
- 2.3.1 CELL LINE GENERATION INDUSTRY TRENDS 10
- 2.3.2 CELL LINE GENERATION MARKET DRIVERS 11
- 2.3.3 CELL LINE GENERATION MARKET CHALLENGES 11
- 2.3.4 CELL LINE GENERATION MARKET RESTRAINTS 12
3 COMPETITION LANDSCAPE BY KEY PLAYERS 13
- 3.1 GLOBAL TOP CELL LINE GENERATION PLAYERS BY REVENUE 13
- 3.1.1 GLOBAL TOP CELL LINE GENERATION PLAYERS BY REVENUE (2017-2022) 13
- 3.1.2 GLOBAL CELL LINE GENERATION REVENUE MARKET SHARE BY PLAYERS (2017-2022) 14
- 3.2 GLOBAL CELL LINE GENERATION MARKET SHARE BY COMPANY TYPE (TIER 1, TIER 2, AND TIER 3) 15
- 3.3 PLAYERS COVERED: RANKING BY CELL LINE GENERATION REVENUE 16
- 3.4 GLOBAL CELL LINE GENERATION MARKET CONCENTRATION RATIO 17
- 3.4.1 GLOBAL CELL LINE GENERATION MARKET CONCENTRATION RATIO (CR5) 17
- 3.5 CELL LINE GENERATION KEY PLAYERS HEAD OFFICE AND AREA SERVED 18
- 3.6 KEY PLAYERS CELL LINE GENERATION PRODUCT SOLUTION AND SERVICE 18
- 3.7 ESTABLISHED DATE CELL LINE GENERATION MANUFACTURER 19
4 CELL LINE GENERATION BREAKDOWN DATA BY TYPE 21
- 4.1 GLOBAL CELL LINE GENERATION HISTORIC MARKET SIZE BY TYPE (2017-2022) 21
- 4.2 GLOBAL CELL LINE GENERATION FORECASTED MARKET SIZE BY TYPE (2023-2028) 22
5 CELL LINE GENERATION BREAKDOWN DATA BY APPLICATION 23
- 5.1 GLOBAL CELL LINE GENERATION HISTORIC MARKET SIZE BY APPLICATION (2017-2022) 23
- 5.2 GLOBAL CELL LINE GENERATION FORECASTED MARKET SIZE BY APPLICATION (2023-2028) 23
6 NORTH AMERICA 25
- 6.1 NORTH AMERICA CELL LINE GENERATION MARKET SIZE (2017-2028) 25
- 6.2 NORTH AMERICA CELL LINE GENERATION MARKET SIZE BY COUNTRY (2017-2022) 25
- 6.3 NORTH AMERICA CELL LINE GENERATION MARKET SHARE BY COUNTRY (2023-2028) 26
- 6.4 UNITED STATES 27
- 6.5 CANADA 27
7 EUROPE 28
- 7.1 EUROPE CELL LINE GENERATION MARKET SIZE (2017-2028) 28
- 7.2 EUROPE CELL LINE GENERATION MARKET SIZE BY COUNTRY (2017-2022) 28
- 7.3 EUROPE CELL LINE GENERATION MARKET SIZE BY COUNTRY (2023-2028) 29
- 7.4 GERMANY 30
- 7.5 FRANCE 30
- 7.6 U.K. 31
- 7.7 ITALY 31
- 7.8 RUSSIA 32
- 7.9 NORDIC COUNTRIES 32
8 ASIA-PACIFIC 33
- 8.1 ASIA-PACIFIC CELL LINE GENERATION MARKET SIZE (2017-2028) 33
- 8.2 ASIA-PACIFIC CELL LINE GENERATION MARKET SIZE BY REGION (2017-2022) 33
- 8.3 ASIA-PACIFIC CELL LINE GENERATION MARKET SIZE BY REGION (2023-2028) 34
- 8.4 CHINA 35
- 8.5 JAPAN 35
- 8.6 SOUTH KOREA 36
- 8.7 SOUTHEAST ASIA 36
- 8.8 INDIA 37
- 8.9 AUSTRALIA 37
9 LATIN AMERICA 38
- 9.1 LATIN AMERICA CELL LINE GENERATION MARKET SIZE (2017-2028) 38
- 9.2 LATIN AMERICA CELL LINE GENERATION MARKET SIZE BY COUNTRY (2017-2022) 38
- 9.3 LATIN AMERICA CELL LINE GENERATION MARKET SIZE BY COUNTRY (2023-2028) 39
- 9.4 MEXICO 40
- 9.5 BRAZIL 40
10 MIDDLE EAST & AFRICA 41
- 10.1 MIDDLE EAST & AFRICA CELL LINE GENERATION MARKET SIZE (2017-2028) 41
- 10.2 MIDDLE EAST & AFRICA CELL LINE GENERATION MARKET SIZE BY COUNTRY (2017-2022) 41
- 10.3 MIDDLE EAST & AFRICA CELL LINE GENERATION MARKET SIZE BY COUNTRY (2023-2028) 42
- 10.4 TURKEY 43
- 10.5 SAUDI ARABIA 43
- 10.6 UAE 44
11 KEY PLAYERS PROFILES 45
- 11.1 BOEHRINGER INGELHEIM BIOXCELLENCE 45
- 11.1.1 BOEHRINGER INGELHEIM BIOXCELLENCE COMPANY DETAILS 45
- 11.1.2 BOEHRINGER INGELHEIM BIOXCELLENCE BUSINESS OVERVIEW 45
- 11.1.3 BOEHRINGER INGELHEIM BIOXCELLENCE CELL LINE GENERATION INTRODUCTION 46
- 11.1.4 BOEHRINGER INGELHEIM BIOXCELLENCE REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 47
- 11.2 LONZA GROUP AG 47
- 11.2.1 LONZA GROUP AG COMPANY DETAILS 47
- 11.2.2 LONZA GROUP AG BUSINESS OVERVIEW 47
- 11.2.3 LONZA GROUP AG CELL LINE GENERATION INTRODUCTION 48
- 11.2.4 LONZA GROUP AG REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 49
- 11.3 WUXI BIOLOGICS 49
- 11.3.1 WUXI BIOLOGICS COMPANY DETAILS 49
- 11.3.2 WUXI BIOLOGICS BUSINESS OVERVIEW 49
- 11.3.3 WUXI BIOLOGICS CELL LINE GENERATION INTRODUCTION 50
- 11.3.4 WUXI BIOLOGICS REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 50
- 11.3.5 WUXI BIOLOGICS RECENT DEVELOPMENT 50
- 11.4 THERMO FISHER SCIENTIFIC 51
- 11.4.1 THERMO FISHER SCIENTIFIC COMPANY DETAILS 51
- 11.4.2 THERMO FISHER SCIENTIFIC BUSINESS OVERVIEW 51
- 11.4.3 THERMO FISHER SCIENTIFIC CELL LINE GENERATION INTRODUCTION 52
- 11.4.4 THERMO FISHER SCIENTIFIC REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 52
- 11.5 SARTORIOUS AG 53
- 11.5.1 SARTORIOUS AG COMPANY DETAILS 53
- 11.5.2 SARTORIOUS AG BUSINESS OVERVIEW 53
- 11.5.3 SARTORIOUS AG CELL LINE GENERATION INTRODUCTION 54
- 11.5.4 SARTORIOUS AG REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 54
- 11.5.5 SARTORIOUS AG RECENT DEVELOPMENT 54
- 11.6 MERCK KGAA 55
- 11.6.1 MERCK KGAA COMPANY DETAILS 55
- 11.6.2 MERCK KGAA BUSINESS OVERVIEW 55
- 11.6.3 MERCK KGAA CELL LINE GENERATION INTRODUCTION 56
- 11.6.4 MERCK KGAA REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 56
- 11.6.5 MERCK KGAA RECENT DEVELOPMENT 56
- 11.7 CATALENT 57
- 11.7.1 CATALENT COMPANY DETAILS 57
- 11.7.2 CATALENT BUSINESS OVERVIEW 57
- 11.7.3 CATALENT CELL LINE GENERATION INTRODUCTION 58
- 11.7.4 CATALENT REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 58
- 11.8 SAMSUNG BIOLOGICS 59
- 11.8.1 SAMSUNG BIOLOGICS COMPANY DETAILS 59
- 11.8.2 SAMSUNG BIOLOGICS BUSINESS OVERVIEW 59
- 11.8.3 SAMSUNG BIOLOGICS CELL LINE GENERATION INTRODUCTION 60
- 11.8.4 SAMSUNG BIOLOGICS REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 60
- 11.9 FUJIFILM DIOSYNTH BIOTECHNOLOGIES 60
- 11.9.1 FUJIFILM DIOSYNTH BIOTECHNOLOGIES COMPANY DETAILS 60
- 11.9.2 FUJIFILM DIOSYNTH BIOTECHNOLOGIES BUSINESS OVERVIEW 61
- 11.9.3 FUJIFILM DIOSYNTH BIOTECHNOLOGIES CELL LINE GENERATION INTRODUCTION 61
- 11.9.4 FUJIFILM DIOSYNTH BIOTECHNOLOGIES REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 62
- 11.10 PORTON BIOLOGICS 62
- 11.10.1 PORTON BIOLOGICS COMPANY DETAILS 62
- 11.10.2 PORTON BIOLOGICS BUSINESS OVERVIEW 62
- 11.10.3 PORTON BIOLOGICS CELL LINE GENERATION INTRODUCTION 63
- 11.10.4 PORTON BIOLOGICS REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 63
- 11.11 CHEMPARTNER PHARMATECH 64
- 11.11.1 CHEMPARTNER PHARMATECH COMPANY DETAILS 64
- 11.11.2 CHEMPARTNER PHARMATECH BUSINESS OVERVIEW 64
- 11.11.3 CHEMPARTNER PHARMATECH CELL LINE GENERATION INTRODUCTION 65
- 11.11.4 CHEMPARTNER PHARMATECH REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 65
- 11.12 RENTSCHLER BIOPHARMA 65
- 11.12.1 RENTSCHLER BIOPHARMA COMPANY DETAILS 65
- 11.12.2 RENTSCHLER BIOPHARMA BUSINESS OVERVIEW 66
- 11.12.3 RENTSCHLER BIOPHARMA CELL LINE GENERATION INTRODUCTION 66
- 11.12.4 RENTSCHLER BIOPHARMA REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 67
- 11.13 PROBIOGEN 67
- 11.13.1 PROBIOGEN COMPANY DETAILS 67
- 11.13.2 PROBIOGEN BUSINESS OVERVIEW 68
- 11.13.3 PROBIOGEN CELL LINE GENERATION INTRODUCTION 68
- 11.13.4 PROBIOGEN REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 68
- 11.14 AGC BIOLOGICS 69
- 11.14.1 AGC BIOLOGICS COMPANY DETAILS 69
- 11.14.2 AGC BIOLOGICS BUSINESS OVERVIEW 69
- 11.14.3 AGC BIOLOGICS CELL LINE GENERATION INTRODUCTION 70
- 11.14.4 AGC BIOLOGICS REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 70
- 11.15 OPM BIOSCIENCES 70
- 11.15.1 OPM BIOSCIENCES COMPANY DETAILS 71
- 11.15.2 OPM BIOSCIENCES BUSINESS OVERVIEW 71
- 11.15.3 OPM BIOSCIENCES CELL LINE GENERATION INTRODUCTION 71
- 11.15.4 OPM BIOSCIENCES REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 72
- 11.16 CHARLES RIVER LABORATORIES 72
- 11.16.1 CHARLES RIVER LABORATORIES COMPANY DETAILS 72
- 11.16.2 CHARLES RIVER LABORATORIES BUSINESS OVERVIEW 73
- 11.16.3 CHARLES RIVER LABORATORIES CELL LINE GENERATION INTRODUCTION 73
- 11.16.4 CHARLES RIVER LABORATORIES REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 74
- 11.17 MYCENAX BIOTECH 74
- 11.17.1 MYCENAX BIOTECH COMPANY DETAILS 74
- 11.17.2 MYCENAX BIOTECH BUSINESS OVERVIEW 75
- 11.17.3 MYCENAX BIOTECH CELL LINE GENERATION INTRODUCTION 75
- 11.17.4 MYCENAX BIOTECH REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 76
- 11.18 JOINN LAB 76
- 11.18.1 JOINN LAB COMPANY DETAILS 76
- 11.18.2 JOINN LAB BUSINESS OVERVIEW 77
- 11.18.3 JOINN LAB CELL LINE GENERATION INTRODUCTION 77
- 11.18.4 JOINN LAB REVENUE IN CELL LINE GENERATION BUSINESS (2017-2022) 78
12 ANALYST'S VIEWPOINTS/CONCLUSIONS 79
13 APPENDIX 80
- 13.1 RESEARCH METHODOLOGY 80
- 13.1.1 METHODOLOGY/RESEARCH APPROACH 80
- 13.1.2 DATA SOURCE 83
- 13.2 DISCLAIMER 86
- 13.3 AUTHOR DETAILS 86